ecancermedicalscience

Research

The occurrence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer not receiving primary G-CSF prophylaxis

2 Nov 2023
Susanna Hilda Hutajulu, Siswi Oktariani, Agus Jati Sunggoro, Bagas Suryo Bintoro, Yufi Kartika Astari, Juan Adrian Wiranata, Irianiwati Widodo, Anita Ekowati, Mardiah Suci Hardianti, Kartika Widayati Taroeno-Hariadi, Johan Kurnianda, Ibnu Purwanto

Background: Chemotherapy-induced neutropenia (CIN) is a substantial side effect in chemotherapy of breast cancer patients. Administration of granulocyte colony stimulating factor (G-CSF) that may reduce CIN occurrence is not commonly available to many local cases.

Objectives: To investigate the occurrence of grade 4 CIN and the influencing factors in breast cancer patients not receiving G-CSF prophylaxis.

Methods: One-hundred and eighty-six newly diagnosed breast cancer patients who received a 3-weekly (neo)adjuvant or palliative chemotherapy without primary G-CSF prophylaxis were included. Grade 4 CIN was defined as absolute neutrophil count (ANC) <0.5 × 103/mm3 during any chemotherapy cycle. We used logistic regression to explore the association of clinical, pathological and treatment factors with the risk of grade 4 CIN in the first cycle and in any given cycle.

Results: Fifty-seven (30.6%) patients experienced grade 4 CIN in the first cycle and 145 (78%) had it at least once during chemotherapy. In the first cycle, haemoglobin, ANC, and albumin levels were associated with grade 4 CIN (OR = 1.48, p = 0.031; OR = 0.68, p = 0.006; and OR = 2.07, p = 0.042). In any cycle, pre-treatment ANC levels and anthracycline-taxane combination regimen were associated with grade 4 CIN (OR = 0.78, p = 0.032 and OR = 3.64, p = 0.012).

Conclusions: A significant proportion of the local breast cancer cases undergoing chemotherapy without primary G-CSF prophylaxis experienced grade 4 CIN. Haemoglobin, ANC, and albumin levels are the risk factors for first cycle CIN, while pre-treatment ANC levels and anthracycline-taxane chemotherapy regimen are associated with CIN in any given cycle. These risk factors may be used to direct a recommendation of G-CSF prophylaxis to the most at-risk individuals in the local setting or other settings in similar situations.

Related Articles

Lingaraj Nayak, Gaurav Salunke, Trupti Gilada, Sukhada Savarkar, Bindiya Salunke, Sanjay Biswas, Vanita Noronha, Atul Kulkarni, Manju Sengar, Akshay Baheti, Pradnya Samant, Anant Gokarn, Anuradha Mehta, Chetan Dhamne, Keerthna Batyala
Sasongko Hadi Priyono, Winardi Budiwinata, Budianto Tedjowitono, Effendy, Muhamad Daffa Ibnurasy Pratama
Ghazal Tansir, Akhil Santhosh, Akash Kumar, Hemavathi Baskarane, Mohit Kumar Divakar, Vishakha Hooda, Arundhati J R Dev, Chandra Prakash Prasad, Ishaan Gupta, Saran Kumar, Pranay Tanwar, Atul Sharma, Sameer Bakhshi, Atul Batra
Muhammad Arif Hameed, Yasmin Abdul Rashid, Insia Ali, Waqas Ahmed Khan, Tasneem Dawood, Misbah Soomro, Mirza Rameez Samar